Technical Analysis for EPZM - Epizyme, Inc.

Grade Last Price % Change Price Change
D 8.67 1.40% 0.12
EPZM closed up 1.4 percent on Thursday, May 13, 2021, on approximately normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical EPZM trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Calm After Storm Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Calm After Storm Range Contraction 1.40%
Overbought Stochastic Strength 1.40%
Upper Bollinger Band Touch Strength 1.40%
20 DMA Support Bullish 1.52%
Crossed Above 50 DMA Bullish 1.52%
Older End-of-Day Signals for EPZM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout about 16 hours ago
Up 1% about 16 hours ago
60 Minute Opening Range Breakdown about 20 hours ago
Down 3% about 20 hours ago
Down 2 % about 20 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Epizyme, Inc. Description

Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Sàrl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Cancers Lymphoma Leukemia Companion Diagnostic Hodgkin Lymphoma Non Hodgkin Lymphoma Eisai Ezh2

Is EPZM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 22.0
52 Week Low 6.7
Average Volume 1,364,409
200-Day Moving Average 11.19
50-Day Moving Average 8.38
20-Day Moving Average 7.98
10-Day Moving Average 7.99
Average True Range 0.53
ADX 15.82
+DI 23.20
-DI 25.69
Chandelier Exit (Long, 3 ATRs ) 7.40
Chandelier Exit (Short, 3 ATRs ) 8.28
Upper Bollinger Band 8.81
Lower Bollinger Band 7.16
Percent B (%b) 0.91
BandWidth 20.71
MACD Line -0.03
MACD Signal Line -0.17
MACD Histogram 0.1399
Fundamentals Value
Market Cap 880.71 Million
Num Shares 102 Million
EPS -1.86
Price-to-Earnings (P/E) Ratio -4.66
Price-to-Sales 113.20
Price-to-Book 6.49
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.56
Resistance 3 (R3) 9.48 9.11 9.41
Resistance 2 (R2) 9.11 8.88 9.15 9.36
Resistance 1 (R1) 8.89 8.75 9.00 8.97 9.31
Pivot Point 8.52 8.52 8.58 8.56 8.52
Support 1 (S1) 8.30 8.29 8.41 8.38 8.03
Support 2 (S2) 7.93 8.16 7.97 7.98
Support 3 (S3) 7.71 7.93 7.93
Support 4 (S4) 7.79